Citius Pharma gets Nasdaq bid-price compliance extension to Feb 8, 2027

Citius Pharmaceuticals, Inc.

Nasdaq granted extension to Feb 8, 2027 to regain compliance with $1.00 bid price rule.
Must close at or above $1.00 for 10 consecutive business days before deadline.
Failure to comply by Feb 8, 2027 triggers delisting notice; company may appeal.
Stock remains listed on Nasdaq Capital Market under CTXR; no immediate effect.
Company evaluating options; no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.